Share Options

RNS Number : 6369R

Deltex Medical Group PLC

25 September 2017

 

25 September 2017

Deltex Medical Group plc

("Deltex Medical" or "the Company")

Share Options

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM") announces the grant of share options to its executive directors under its Employee Share Option Scheme and the exercise by an employee of 97,560 share options under the Company's Enterprise Management Incentive scheme ('EMI').

Employee Share Option Scheme

The Board has approved the grant of 2,500,000 and 1,562,500 share options to Ewan Phillips and Jonathan Shaw respectively under the Company's 2011 Executive Share Option Scheme. The exercise price is 4 pence per share option, a premium of 23% over the closing price on 22 September 2017. These share options may ordinarily be exercised between September 2020 and September 2027 subject to relevant performance conditions which are based on achieving certain levels of compound annual sales growth.

Confirmation of Directors interest in share options

Following the grant of EMI options above, the options held by the Executive Directors are shown below:

Executive Director	2001 Executive Share Scheme	2011 Executive Share Scheme	EMI Share Scheme	Total
	Number	Number	Number	Number
Ewan Phillips	1,000,000	5,250,000	2,995,954	9,245,954
Jonathan Shaw	-	1,562,500	404,762	1,967,262

Additional interests

Mr Phillips and Mr Shaw have beneficial interests in 2,921,051 and 262,931 ordinary shares in the Company respectively. Following the share option exercise referred to above these holdings will represent 0.93 per cent and 0.08 per cent of the issued ordinary share capital of the Company.

Exercise of EMI share options

The Company has also issued 97,560 new Ordinary Shares of 1 pence each in the capital of the Company ("Ordinary Shares") following the exercise of options by an employee granted under the Company's EMI share option scheme. The options had an exercise price of 1 pence per share and the notice of exercise was received on 13 September 2017. Application has been made for the 97,560 new Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on 29 September 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 313,213,367. The Company does not hold any shares in treasury. Accordingly, the figure of 313,213,367 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

The following notifications are made in accordance with Article 19 of the EU Market Abuse Regulation

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Ewan Phillips
2	Reason for the notification
a)	Position/status	Executive Director
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Deltex Medical Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Conditional awards over Ordinary shares of 1p each in Deltex Medical Group plc Identification code (ISIN) for Deltex Medical Group plc ordinary shares: GB0059337583
b)	Nature of the transaction	Grant of Share Options
c)	Price(s) and volume(s)	Conditional award over 2,500,000 shares under the Deltex Medical Group Executive Share Option Scheme 2011
d)	Aggregated information - Aggregated volume - Price
e)	Date of the transaction	22 September 2017
f)	Place of the transaction	Grant of share awards occurred outside of a trading venue.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jonathan Shaw
2	Reason for the notification
a)	Position/status	Executive Director
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Deltex Medical Group plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Conditional awards over Ordinary shares of 1p each in Deltex Medical Group plc Identification code (ISIN) for Deltex Medical Group plc ordinary shares: GB0059337583
b)	Nature of the transaction	Grant of Share Options
c)	Price(s) and volume(s)	Conditional award over 1,562,500 shares under the Deltex Medical Group Executive Share Option Scheme 2011
d)	Aggregated information - Aggregated volume - Price
e)	Date of the transaction	22 September 2017
f)	Place of the transaction	Grant of share awards occurred outside of a trading venue.

For further information, please contact:

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Jonathan Shaw, Group Finance Director
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie Ciaran Walsh

Joint Broker
Turner Pope Investments (TPI) Ltd	0203 621 4120 [e-mail]
Ben Turner James Pope
Financial Public Relations
IFC Advisory Ltd	0203 053 8671
Tim Metcalfe Graham Herring Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

END

 

 

DSHUSUNRBUAKUAR